Yehuda Ringel

Biomica Ltd. engages in the provision of biopharmaceutical services. Its technology focuses on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. The company was founded by Yehuda Ringel in 2017 and is headquartered in Rehovot, Israel.

Biomica Ltd. engages in the provision of biopharmaceutical services. Its technology focuses on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. The company was founded by Yehuda Ringel in 2017 and is headquartered in Rehovot, Israel.

Biomica Ltd. engages in the provision of biopharmaceutical services. Its technology focuses on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. The company was founded by Yehuda Ringel in 2017 and is headquartered in Rehovot, Israel.

Biomica Ltd. engages in the provision of biopharmaceutical services. Its technology focuses on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. The company was founded by Yehuda Ringel in 2017 and is headquartered in Rehovot, Israel.

Biomica Ltd. engages in the provision of biopharmaceutical services. Its technology focuses on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. The company was founded by Yehuda Ringel in 2017 and is headquartered in Rehovot, Israel.